112 completed, 67 recruiting, 58 unknown, 19 terminated. 175 Phase 2, 77 Phase 3, 58 Phase 1, 13 Not applicable, 6 Phase 4.
Follow Folfox protocol: new trials by email Literature Review of Folfox protocol trials Research Report on Folfox protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu - Gastroesophageal Adenocarcinoma | Phase 3 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 244 | 2026-09-01 | 2026-08-18 |
| Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Esophageal Adenocarcinoma | Phase 2 | Recruiting | Duke University | 60 | 2026-09-01 | 2026-09-29 |
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer | Phase 3 | Active not recruiting | UNICANCER | 2450 | 2026-07-20 | 2026-07-22 |
| KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer KRC-01 (KORTUC), Radiotherapy, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 24 | 2026-07-01 | 2026-06-02 |
| Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer Mitomycin (MM), FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Cytoreductive surgery - Locally Advanced Colorectal Cancer | Phase 3 | Recruiting | Maimónides Biomedical Research Institute of Córdoba | 1083 | 2026-05-26 | 2026-06-08 |
| Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer SAR445877, FOLFOX6, Bevacizumab - Phase 1, SAR445877 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 41 | 2026-05-20 | 2026-07-23 |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab - Adebrelimab (SHR-1316), Bevacizumab | Phase 2 | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 38 | 2026-04-10 | 2026-04-28 |
| HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer HAIC(GOLF), Bevacizumab, PD-1/PD-L1 inhibitor - Biliary Tract Cancer (BTC) | Not applicable | Recruiting | Peking University | 40 | 2026-03-31 | 2026-05-08 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) Pumitamig, Folfox, Capox - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 690 | 2026-03-13 | 2026-09-30 |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer INCA33890, Placebo, Bevacizumab - CRC (Colorectal Cancer) | Phase 3 | Recruiting | Incyte Corporation | 700 | 2026-03-05 | 2026-10-09 |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Not yet recruiting | J. W. A. Burger | 394 | 2026-03-03 | 2026-03-16 |
| CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-001, Paclitaxel, trifluridine and tipiracil - Locally Advanced / Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 540 | 2026-02-17 | 2026-10-20 |
| FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma hepatic arterial infusion chemotherapy (HAIC), Donafenib, Pucotenlimab - Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 36 | 2026-02-01 | 2026-01-20 |
| A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer Inavolisib, Bevacizumab, FOLFOX - Colorectal Cancer | Phase 2 | Withdrawn | Hoffmann-La Roche | 2026-02-01 | 2026-02-09 | |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 990 | 2025-12-31 | 2026-09-23 |
| Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373 - Colorectal Cancer Metastatic | Early Phase 1 | Recruiting | Northwell Health | 10 | 2025-12-10 | 2026-06-24 |
| Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Balstilimab, Botensilimab, Folfox Protocol - Gastric Cancer, MSI-H | Phase 3 | Recruiting | Centre Leon Berard | 132 | 2025-12-08 | 2026-06-25 |
Showing 20 of 295. Sign in to see all of them.
Colorectal Neoplasms (129) · Colonic Neoplasms (54) · Rectal Neoplasms (49) · Carcinoma, Hepatocellular (29) · Stomach Neoplasms (24) · Neoplasm Metastasis (23) · Neoplasms (11) · Adenocarcinoma Of Esophagus (10) · Pancreatic Neoplasms (10) · Cholangiocarcinoma (9) · Esophageal Neoplasms (7) · Biliary Tract Neoplasms (6) · Liver Neoplasms (6) · Gastrointestinal Neoplasms (5) · Breast Neoplasms (4)
Sun Yat-sen University (21) · Fudan University (9) · UNICANCER (8) · GERCOR - Multidisciplinary Oncology Cooperative Group (6) · Alliance for Clinical Trials in Oncology (5) · AstraZeneca (5) · Bristol-Myers Squibb (4) · Eli Lilly and Company (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Federation Francophone de Cancerologie Digestive (4) · Genentech, Inc. (4) · National Cancer Institute (NCI) (4) · Sixth Affiliated Hospital, Sun Yat-sen University (4) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Hoffmann-La Roche (3)
United States (96) · China (76) · France (56) · Spain (30) · Italy (29) · Canada (26) · South Korea (24) · Germany (22) · United Kingdom (21) · Belgium (18) · Australia (17) · Netherlands (13) · Poland (12) · Austria (11) · Japan (10)
Ming Shi, MD (6) · Jane Robertson (4) · Aimery de Gramont, MD (2) · Chia Portera, M.D. (2) · Fortunato Ciardiello (2) · Johanna C Bendell, M.D. (2) · Matthew T. Seymour, MA, MD, FRCP (2) · Ming Zhao, M.D. & Ph.D. (2) · Nancy E. Kemeny, MD (2)
PMID 36306483, PMID 12049862, PMID 20839057, PMID 23980077, PMID 30679026, PMID 31378656, PMID 34905388, PMID 9149014, PMID 10493478, PMID 11981766, PMID 12229948, PMID 12540794, PMID 12860947, PMID 15383798, PMID 15496622, PMID 15623449, PMID 15868235, PMID 16009951, PMID 16009952, PMID 16110021, PMID 16177017, PMID 16356309, PMID 16813588, PMID 16877722, PMID 16971718, PMID 16983741, PMID 17008704, PMID 17175450, PMID 17553204, PMID 17630037, PMID 17785765, PMID 17968156, PMID 18279058, PMID 18358928, PMID 18452860, PMID 18477802, PMID 18650514, PMID 18981005, PMID 19203899, PMID 19233901, PMID 19269519, PMID 19554377, PMID 19826418, PMID 19858398, PMID 19884549, PMID 19942479, PMID 20395841, PMID 20632311, PMID 20686792, PMID 20692872
2025 (10), 2023 (5), 2009 (3), 2016 (2), 2017 (2), 2018 (2), 2019 (2), 2005 (1), 2014 (1), N01CM62206 (1), P30CA008748 (1), P30CA016087 (1), P30CA033572 (1), U01CA069856 (1), U10CA031946 (1)